Abstract:The goal of this research was to find a way to enhance the pharmacological activity of Capecitabine (CAP) and Thymoquinone (TQ) while also decreasing the likelihood of drug resistance by studying the synergistic activity of TQ, formulating the functionalized polymeric nanoparticles (PNPs) as carriers for effectively targeting the colon to manage colorectal cancer (CRC). CAP and TQ-loaded galactosylated PLGA nanoparticles coated with Eudragit-S-100 were created and optimized to target the colon's pH for drug release after oral delivery using Box-Behnken design. The standard study revealed that they had a high stability of normal pH, a tiny size of spherical shape droplets, and a unique zeta potential that was non-toxic and promoted faster cell migration. Cancer cells treated with PNPs that had a protective effect on intracellular reactive oxygen species (ROS), oxidative stress, and mitochondrial membrane potential had their apoptotic morphology altered to promote cell survival. Moreover, the investigation of pharmacodynamics on male Wistar rats unveiled a notable reduction in the number of tumors, aberrant crypt foci, accompanied by a discernible amelioration in dysplastic characteristics and enhancement in various blood parameters, and its toxic effects were mitigated proving Galactosylation to be a reliable method which has shown to be useful in targeting CRC through galectin-mediated endocytosis. When compared to free CAP, the targeted approach increases cytotoxicity and cell death. The data demonstrated that the targeted method maximized the efficacy of CAP in regulating tumor development, enhancing apoptosis and decreasing drug resistance. This demonstrated that the engineered PNP showed encouraging anticancer activity with less toxicity and may be employed as an efficient carrier against cancer. Docking research stated that TQ had the maximum binding affinity to Mitogen-activated protein kinase kinase molecule which is inextricably linked to colon cancer (binding energy −6.07 kcal/mol). This is the first work to our knowledge to demonstrate that eudragit S-100 coated CAP and TQ-loaded Galactosylated PLGANP can induce apoptosis, which could be used to kill off cancer cells. Graphical abstract Download : Download high-res image (293KB) Download : Download full-size image

Co-amorphous mixture of Erlotinib hydrochloride and Gallic acid for enhanced antitumor effects

Solid amorphous formulations for enhancing solubility and inhibiting Erlotinib crystallization during gastric-to-intestinal transfer

Manifesting the Dasatinib-gallic acid co-amorphous system to augment anticancer potential: Physicochemical characterization, in silico molecular simulation, ex vivo permeability, and in vitro efficacy

Synthesis, Molecular Docking and Biological Evaluation of Glycyrrhizin Analogs As Anticancer Agents Targeting EGFR.

FORMULATION AND CHARACTERIZATION OF THERMOSENSITIVE CHITOSAN HYDROGEL LOADED WITH ERLOTINIB: FULL FACTORIAL DESIGN OF RELEASE DATA

Gefitinib encapsulation based on nano-liposomes for enhancing the curative effect of lung cancer

Preparation of a camptothecin analog FLQY2 self-micelle solid dispersion with improved solubility and bioavailability

Computational-Based Polyphenol Therapy for Nonsmall Cell Lung Cancer: Naringin Coamorphous Systems for Solubility and Bioavailability Enhancement

Improving Anti-Cancer Potentiality and Bioavailability of Gallic Acid by Designing Polymeric Nanocomposite Formulation

Gallic acid-loaded HFZIF-8 for tumor-targeted delivery and thermal-catalytic therapy

Engineering EHD1-Targeted Natural Borneol Nanoemulsion Potentiates Therapeutic Efficacy of Gefitinib against Nonsmall Lung Cancer

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

A novel drug-drug cocrystal of tegafur and myricetin: optimized properties of dissolution and tabletability

Antitumor effects of erlotinib in combination with berberine in A431 cells

The Role of Self-Nanoemulsifying Drug Delivery Systems of CDODA-Me in Sensitizing Erlotinib-Resistant Non-Small Cell Lung Cancer

Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer.

Injectable Thermosensitive Hydrogel Containing Erlotinib‐Loaded Hollow Mesoporous Silica Nanoparticles as a Localized Drug Delivery System for NSCLC Therapy

Improvement of the Cytotoxicity and Tumor Selectivity of Glycyrrhetinic Acid by Derivatization with Bifunctional Aminoacids

Gambogic acid and IR780 self-assembled nanoparticles for combined chemo-phototherapy

Development of o-aminobenzamide salt derivatives for improving water solubility and anti-undifferentiated gastric cancer

An innovative synergistic combination using eudragit-coated galactosylated PLGA-pluronic nanoparticles for addressing colorectal cancer